Allogene Therapeutics Company

Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by world-class management with significant experience in cell therapy, our fully integrated, in-house team of researchers is dedicated to discovery and translational research, development, and cell manufacturing.

Estimated Revenue: $1M to $10M
Funding Status: IPO
Headquarters: United States
Founded Date: 01.01.2017
Technology: Сancer Diagnostics
Industry: Genomic and Epigenominc Instabillity